Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations-Reference-Cited by-同舟云学术

Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations

Published:2006-03-16 Issue:6 Volume:20 Page:1103-1108
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Gorello P,Cazzaniga G,Alberti F,Dell'Oro M G,Gottardi E,Specchia G,Roti G,Rosati R,Martelli M F,Diverio D,Coco F Lo,Biondi A,Saglio G,Mecucci C,Falini B

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2404149.pdf

Reference19 articles.

1. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731–1738.

2. Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter ‘AIDA’ trial. GIMEMA-AIEOP Multicenter ‘AIDA’ Trial. Blood 1998; 92: 784–789.

3. Vidriales MB, San-Miguel JF, Orfao A, Coustan-Smith E, Campana D . Minimal residual disease monitoring by flow cytometry. Best Pract Res Clin Haematol 2003; 16: 599–612.

4. Guerrasio A, Pilatrino C, De Micheli D, Cilloni D, Serra A, Gottardi E et al. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT–PCR amplification of fusion transcripts. Leukemia 2002; 16: 1176–1181.

5. Krauter J, Gorlich K, Ottmann O, Lubbert M, Dohner H, Heit W et al. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. J Clin Oncol 2003; 21: 4413–4422.

Cited by 259 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-Life Management of FLT3-Mutated AML: Single-Centre Experience over 24 Years;Cancers;2024-08-17

2. Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?;Blood Reviews;2024-08

3. Evaluation of a New Closed-System Automated RT-qPCR Assay for the Rapid Detection and Monitoring of Common Nucleophosmin Mutations in Patients with Acute Myeloid Leukemia;International Journal of Molecular Sciences;2024-07-19

4. Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia;Hematological Oncology;2024-03

5. Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts;International Journal of Molecular Sciences;2024-02-10